Sponsors (2)
The bill provides timely, science-based PFAS clinical guidance and community input to improve detection and care, but does so at the cost of added implementation expenses for health systems and administrative/funding burdens and carries a risk of delays in delivering guidance.
State and local public-health agencies, clinicians, and patients will receive up-to-date, evidence-based clinical guidance on PFAS within 5 years (with mandated updates at least every 5 years), improving diagnosis, patient management, and public-health responses.
Clinicians, hospitals, and patients will benefit from a rigorous scientific assessment identifying which PFAS are measurable in human tissues within 2 years, enabling better detection of exposure and more informed clinical and public-health action.
PFAS-exposed communities—especially low-income and rural communities—will have formal opportunities to engage and inform assessments, increasing the relevance and responsiveness of guidance to local needs.
Hospitals, health systems, and clinicians will face additional costs and operational burdens to implement recommended PFAS testing, follow-up, and new clinical protocols.
PFAS-exposed communities and state/local public-health agencies may experience delays in receiving actionable guidance if the contracted assessment is delayed or if selection of an alternate contractor takes extra time.
ATSDR and partner agencies may incur increased federal spending and administrative burden to contract for, produce, and regularly update the required assessments and guidance.
Based on analysis of 2 sections of legislative text.
Directs ATSDR to contract for periodic scientific assessments of measurable PFAS in human tissues and to publish clinical recommendations and guidance for health authorities and clinicians.
Requires the ATSDR Director to contract with the National Academies (or another qualified entity) to assess which PFAS chemicals are measurable in human tissues and to develop clinical recommendations based on that assessment. The contract must be entered within 60 days of enactment; the initial assessment and recommendations are due within 2 years and must be updated at least every 5 years. Using the assessment, ATSDR must publish and distribute clinical guidance to state and local public health authorities and relevant health care professionals within 5 years of the contract and then at least every 5 years thereafter (or sooner if needed).
Official title: To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.
Introduced January 8, 2026 by Maxine Dexter · Last progress January 8, 2026